A Phase 1 First-in-Human Open-label Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With a Specific KRAS Mutation.
This research study is being done to test the effects of a new investigational drug therapy called AMG 510 which is being investigated for the treatment of advanced solid tumors with a specific KRAS mutation.
This is a Phase 1 first in human, open-label study evaluating the safety, tolerability, pharmacokinetics, and Efficacy, of AMG 510 in Subjects with Advanced Solid Tumors with a Specific KRAS Mutation.
Participants will be compensated for their participation.
- IRB Number: 1806140760 (20170543)
- Research Study Identifier: TX9005
- Principal Investigator: Greg Durm, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required